13F Holdings
中文EN

CGON CG Oncology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1991792 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY183.6%
TTM net income YoY-56.8%
TTM EPS YoY-34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,293.5%
Net margin-3,851.1%
FCF margin-3,068.0%
EBITDA margin-4,237.7%

Returns

ROE-28.3%
ROA-26.7%
ROIC (approx.)-26.0%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets5.3%
Debt / equity0.00x
Current ratio21.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue30.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$4.04M$1.14M$204,000
R&D expense$116.64M$82.10M$45.75M
SG&A expense$73.53M$33.70M$9.90M
Operating income-$190.77M-$114.67M-$55.45M
Income tax-$270,000$1,000$1,000
Net income-$161.00M-$88.04M-$48.61M
EBITDA-$189.33M-$114.63M-$55.43M
EPS (basic)-2.08-1.41-15.65
EPS (diluted)-2.08-1.41-15.65
Weighted avg. shares (diluted)77.30M62.50M4.33M
Balance sheet
Cash & equivalents$32.49M$257.07M$8.27M
Short-term investments$709.66M$484.93M$179.41M
Receivables$688,000$0—
Inventory$1.56M$0—
Current assets$759.48M$754.21M$194.12M
PP&E, net$15.60M$272,000$69,000
Goodwill$10.30M$0—
Intangibles$575,000$0—
Total assets$791.59M$754.80M$199.30M
Current liabilities$30.84M$21.37M$14.25M
Long-term debt$3.00M$0—
Total debt$3.00M$0—
Total liabilities$38.99M$21.42M$14.51M
Shareholders' equity$752.60M$733.38M-$123.10M
Net debt-$29.49M-$257.07M—
Shares outstanding80.69M76.15M5.22M
Cash flow statement
Operating cash flow-$132.35M-$78.71M-$45.68M
Capital expenditure$134,000$234,000—
Free cash flow-$132.48M-$78.95M—
Investing cash flow-$245.82M-$300.76M-$121.19M
Financing cash flow$153.59M$628.28M$87.00M
Depreciation & amortization$1.45M$32,000$17,000
Stock-based compensation$26.68M$11.40M$1.53M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.